Yet the celebration was always tempered by an uncomfortable arithmetic problem. KRAS G12C accounts for only a minority of KRAS-driven cancers. The most common oncogenic variants, including G12D, G12V, and Q61 mutations, dominate pancreatic and colorectal disease and lack the reactive cysteine that made the first-generation inhibitors possible. A comprehensive review published in Medical Oncology by Srijita Chatterjee, Swati Arya, and colleagues surveys this rapidly shifting landscape, arguing that the field is now moving decisively beyond allele-specific G12C inhibition toward a strategy that is mutation- and context-dependent. The review synthesizes patent filings, clinical trial data, and preclinical discoveries to map where KRAS drug development is heading next.

Among the most consequential new chemical entities are non-covalent inhibitors that do not depend on a cysteine residue. MRTX1133, developed through structure-based design, binds the inactive, GDP-bound state of KRAS G12D with nanomolar selectivity and demonstrated striking anti-tumor activity in preclinical pancreatic cancer models. Its clinical descendants are now in human trials, and the commercial stakes are enormous. In 2025, Bayer announced a global license agreement with Kumquat Biosciences for the KRAS G12D inhibitor KBQ548, a deal valued at up to 1.3 billion dollars, while Verastem Oncology exercised its option for rights outside China to the G12D inhibitor GFH375, also known as VS-7375. These transactions signal that major pharmaceutical companies view non-G12C KRAS inhibition as the next major oncology franchise.

Perhaps the most conceptually ambitious approach comes from a different mechanistic family altogether: the tri-complex, or molecular glue, inhibitors. Compounds such as RMC-6236, a pan-RAS(ON) antagonist, do not simply occupy a pocket on KRAS. Instead, they chaperone KRAS into a complex with cyclophilin A, remodeling the protein’s surface so that it can no longer engage its downstream effectors, regardless of which mutation drives the cancer. Because this mechanism is largely mutation-agnostic, a single drug could in principle treat the entire spectrum of RAS-driven tumors. The related molecule RMC-9805 applies the same logic selectively to KRAS G12D, and early clinical presentations have reported encouraging antitumor activity with favorable safety profiles. The review highlights how these agents, discussed intensively at recent ESMO congresses, have moved from academic curiosity to some of the most closely watched programs in clinical oncology.

A third frontier is protein degradation rather than inhibition. ASP3082, a KRAS-directed degrader, recruits the cell’s ubiquitin-proteasome machinery to eliminate mutant KRAS itself rather than merely silencing it. Early reports describe efficacy in KRAS G12D-mutant non-small-cell lung cancer with a manageable toxicity profile. Degradation offers theoretical advantages over occupancy-based inhibition: it removes all of the protein’s scaffolding and effector functions at once, and it may sidestep some resistance mechanisms that arise when residual inhibitor-bound protein retains partial activity. The patent landscape reflects this diversification. World Intellectual Property Organization filings now cover KRAS G12D inhibitors, deuterated KRAS G12D compounds, macrocyclic RAS inhibitors, pan-KRAS inhibitors spanning G12A, G12C, G12D, G12R, G12S, G12V, G13D, and Q61H variants, KRAS G12V-specific inhibitors, and even farnesyltransferase inhibitors repurposed for KRAS-dependent cancers.

No single agent, however, is likely to conquer KRAS-driven cancer alone, and the review devotes substantial attention to rational combination strategies. Upstream of KRAS, the guanine nucleotide exchange factors SOS1 and SHP2 regulate reactivation of the pathway, and blocking them can prevent the feedback activation of wild-type RAS that otherwise constrains G12C inhibitor efficacy. Downstream, MEK inhibitors such as VS-6766 have shown clinical activity in KRAS-mutant cancers, and SHP2 inhibition has been shown to prevent adaptive resistance to MEK blockade across multiple models. In colorectal cancer, where EGFR signaling provides a potent escape route, combining KRAS G12C inhibitors with anti-EGFR antibodies has produced some of the field’s most impressive results: sotorasib plus panitumumab, adagrasib with or without cetuximab, and the next-generation inhibitor divarasib plus cetuximab have all demonstrated substantially improved response rates in refractory disease. Other rational pairings include CDK4/6 inhibitors for KRAS-mutant pancreatic cancer and immune checkpoint inhibitors, exploiting the fact that some KRAS inhibitors appear to enhance anti-tumor immunity.

Resistance, predictably, has emerged as the central clinical challenge. Acquired resistance to sotorasib and adagrasib arises through secondary mutations in KRAS itself, bypass activation of downstream MAPK signaling, and histologic transformation. Co-mutation patterns matter enormously: tumors harboring concurrent STK11/LKB1 alterations show both reduced immunotherapy benefit and distinctive resistance to KRAS inhibition, partly through an adeno-to-squamous transition that reprograms tumor identity. Epithelial-to-mesenchymal transition, a developmental program hijacked by cancer cells, drives both intrinsic and acquired resistance, while non-genetic adaptive mechanisms, including cell-type-specific rewiring of signaling networks, allow tumors to tolerate drug pressure without any new mutation at all. Liquid biopsies that detect circulating tumor DNA are becoming essential tools for monitoring these resistance mechanisms in real time, offering a dynamic alternative to tissue re-biopsy and enabling earlier switches in therapy.

The synthetic lethality concept, first articulated in the 1990s as a framework for anticancer drug discovery, provides another lens for exploiting KRAS addiction. Because mutant KRAS forces cancer cells into a state of profound dependency on compensatory pathways, inhibiting a partner gene that the cancer cell cannot survive without, even when that gene is dispensable in healthy cells, offers a therapeutic window. Screening efforts continue to identify such vulnerabilities, and the review argues that pairing these genetic insights with the new inhibitor classes could produce combinations tailored to the specific constellation of mutations within each patient’s tumor, an approach squarely aligned with the goals of precision oncology.

The regulatory and commercial environment surrounding these advances is itself a story of global competition and opportunity. Patent filings from Mirati Therapeutics, Array Biopharma, and numerous other applicants reveal an intense race to claim chemical space around KRAS, including combination patents pairing G12D inhibitors with SOS1 inhibitors. Clinical trial registries list dozens of active studies, and press releases announcing billion-dollar licensing deals now arrive with regularity. For patients with pancreatic cancer, where KRAS mutation is essentially universal and five-year survival remains dismal, the acceleration cannot come soon enough. The review’s authors conclude that the field has entered a genuinely new era: the question is no longer whether KRAS can be drugged, but which drug, which combination, and which molecular context will deliver the greatest benefit. As allele-specific inhibitors give way to pan-KRAS antagonists, degraders, and intelligently designed combinations, KRAS-mutant cancers are being transformed from a monolithic, untreatable category into a set of molecularly defined diseases, each with its own map of vulnerabilities and its own path to clinical translation.

Subject of Research: Emerging therapeutic strategies and clinical progress in targeting KRAS-mutant cancers beyond KRAS G12C inhibition

Article Title: Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

Article References: Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. (n.d.). https://doi.org/10.1007/s12032-026-03392-6

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03392-6

Keywords: KRAS, KRAS G12C, KRAS G12D inhibitors, pan-KRAS inhibitors, RMC-6236, sotorasib, adagrasib, protein degraders, SHP2 inhibition, drug resistance, pancreatic cancer, precision oncology

Central to this research is the KRAS gene, a critical component in the regulation of cell proliferation and survival. Under normal physiological conditions, RAS proteins cycle between active and inactive forms, effectively acting as molecular switches that govern cell division. However, mutations in the KRAS gene, particularly the G12C variant, lock the protein in an active conducting state, incessantly signaling cells to multiply, thereby fueling cancer growth. This mutation is unfortunately prevalent in NSCLC, present in approximately 10-14% of cases, and is known for driving tumor progression and therapeutic resistance.

The first study within this publication reveals a sophisticated escape mechanism employed by cancer cells treated with KRAS G12C inhibitors. Despite initial therapeutic effectiveness, tumors rapidly reactivate RAS signaling pathways to circumvent inhibition, fostering resistance and disease progression. Importantly, the research introduces next-generation RAS(ON) inhibitors, exemplified by the compound RMC-7977, capable of targeting not only the mutant KRAS but also the wild-type RAS proteins. This dual-targeting approach effectively blocks multiple resistance pathways, thereby reinstating control over tumor growth and offering a robust strategy against adaptive resistance.

Parallel to these findings, the second study explores vulnerabilities in the cellular machinery that cancer cells develop as they adapt to KRAS inhibition. Researchers identified that resistance correlates with heightened dependency on CDK12 and CDK13, cyclin-dependent kinases critical for mediating DNA damage repair and mitotic control. By selectively inhibiting CDK12/13, the team induced mitotic arrest—effectively halting cell division—which culminated in the selective elimination of resistant cancer cells. This intervention exploits the tumor’s acquired reliance on DNA repair pathways to survive, turning a resistance mechanism into a therapeutic target.

Crucially, combining KRAS G12C inhibitors with CDK12/13 inhibitors produced a synergistic effect that delayed or entirely prevented the emergence of resistant cancer cell populations in both in vitro and in vivo models. This co-treatment strategy not only prolonged the duration of treatment efficacy but also circumvented more complex resistance mechanisms, such as those independent of RAS signaling and related to epithelial-mesenchymal transition (EMT), a phenotypic change often associated with increased metastatic potential.

This dual-pronged therapeutic approach addresses one of the central challenges in targeted cancer treatments: the inevitability of resistance. The durability of KRAS G12C inhibitors has been limited by rapid tumor adaptation via genetic and non-genetic routes. By innovatively targeting the active state of RAS proteins through RAS(ON) inhibitors and exploiting the enhanced dependence on DNA repair mechanisms with CDK12/13 blockade, these studies propose a coherent framework to not only delay resistance but also mechanistically dismantle the cancer cell’s survival strategies.

Mechanistically, RAS(ON) inhibitors differ fundamentally from earlier KRAS G12C inhibitors, which primarily target the inactive GDP-bound state of the protein. Targeting the active GTP-bound form allows RAS(ON) inhibitors to simultaneously inhibit both mutant and wild-type RAS isoforms, which tumor cells often co-opt to evade therapy. This wider blockade of RAS signaling pathways eliminates alternate routes tumors exploit, thereby tightening the therapeutic lock on tumor proliferation.

Entry of CDK12/13 inhibitors into this therapeutic schema is equally strategic. CDK12 and CDK13 orchestrate transcriptional elongation of genes involved in DNA repair and cell cycle progression. Tumors resistant to KRAS inhibition become increasingly reliant on these kinases to manage genomic integrity and navigate mitosis successfully. Pharmacologic inhibition of CDK12/13 disrupts these essential processes, inducing catastrophic mitotic arrest and promoting tumor cell death specifically in resistant cell populations.

The clinical implications of these findings are profound. By mapping the molecular underpinnings of resistance in unprecedented detail, the research lays the groundwork for future clinical trials that can implement combination treatments, precisely timed and tailored to prevent or counteract resistance. Such an approach promises to enhance therapeutic durability, improve progression-free survival, and ultimately transform the prognosis for patients harboring KRAS G12C mutations.

These studies underscore the importance of a multifaceted assault on cancer cells, addressing both the primary oncogenic drivers and the secondary adaptations that enable tumor persistence. The research also illustrates the power of translational science, where detailed molecular insights are rapidly integrated into rational therapeutic design, setting the stage for innovative clinical interventions that could shift the current paradigms of lung cancer management.

Moreover, the adoption of RAS(ON) inhibitors widens the potential of targeted therapies beyond KRAS G12C to possibly include other RAS-driven malignancies, given the central role of RAS signaling in numerous cancers. Similarly, CDK12/13 inhibitors hold promise as part of a larger arsenal aimed at disrupting DNA repair and cell cycle pathways exploited by resistant tumors, suggesting broader applications across cancer types.

In summary, the pioneering research conducted at Moffitt Cancer Center delivers a compelling strategy to confront one of the most pressing obstacles in cancer therapeutics: resistance. By simultaneously targeting the reactivation of RAS signaling and the compensatory dependence on DNA repair through CDK12/13 inhibition, these studies offer hope for more durable and effective treatments for the many patients battling KRAS G12C-mutant non-small cell lung cancer.

Such transformative insights are supported by robust experimental models and herald a new chapter in precision oncology, where an intimate understanding of tumor biology informs the design of next-generation combination therapies. As these findings progress toward clinical validation, they may soon redefine standards of care, providing a beacon of hope in the fight against one of the deadliest forms of cancer.

Subject of Research: Cells

Article Title: Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors

News Publication Date: 30-Oct-2025

Web References:

• https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-25-0450/766922/Targeting-CDK12-13-Drives-Mitotic-Arrest-to?redirectedFrom=fulltext
• https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-25-0600/766923/RAS-GTP-Inhibition-Overcomes-Acquired-Resistance?redirectedFrom=fulltext

References:
Supported by the National Cancer Institute (5R01CA262530-0, P30-CA076292) and State of Florida Bankhead Coley Grant (5BC07).

Keywords: Lung cancer, KRAS G12C mutation, drug resistance, RAS(ON) inhibitors, CDK12/13 inhibition, mitotic arrest, targeted cancer therapy, non-small cell lung cancer, therapeutic resistance mechanisms